Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax plus chemotherapy in newly diagnosed AML (risk-stratified)
ChiCTR2400090001Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: 2-year event-free survival rate. Started Oct 2024; status: completed.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400090001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090001.